Eunmee Yook, MD
Ophthalmology · Houston, TXNPI 1669715504
Payments from drug & device makers
Across 142 payments — averaging $44.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alcon$969
- Glaukos Corporation$951
- NEW World Medical,inc.$570
- Aerie Pharmaceuticals, Inc.$302
- Ivantis, Inc$143
- plus $253 from 6 others
What the payments were for
- Consulting fees$90014%
- Food & beverage$5,40286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $3,112 |
| Alcon | 37 | $969 |
| Glaukos Corporation | 9 | $951 |
| NEW World Medical,inc. | 8 | $570 |
| Aerie Pharmaceuticals, Inc. | 5 | $302 |
| Ivantis, Inc | 1 | $143 |
| Bausch & Lomb Americas Inc. | 5 | $104 |
| Thea Pharma Inc. | 3 | $61 |
| Sight Sciences, Inc. | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Dompe US, Inc. | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$1,025
- Kahook Dual Blade$471
- Ahmed Glaucoma Valve$471
- XEN GLAUCOMA TREATMENT SYSTEM$468
- Hydrus Microstent$390
- LUMIGAN$354
- iDose$328
- Clearpath$324
- Streamline$324
- Via360$324
- iStent inject W$162
- KXL System$162
- Photrexa$162
- Streamline Surgical System$147
- Unity$147
- ALPHAGAN P$125
- Rhopressa$124
- Rocklatan$124
- COMBIGAN$109
- iStent Trabecular Micro-Bypass System Model iS3$107
How this compares
$6,302 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 326 | $193,581 |
| CombiganBrimonidine Tartrate/Timolol | 179 | $84,308 |
| RhopressaNetarsudil Mesylate | 85 | $61,534 |
| RocklatanNetarsudil Mesylat/Latanoprost | 74 | $59,700 |
| Alphagan PBrimonidine Tartrate | 120 | $58,446 |
| RestasisCyclosporine | 25 | $40,630 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 174 | $35,887 |
| Prednisolone Acetate | 343 | $19,542 |
| VyzultaLatanoprostene Bunod | 39 | $18,615 |
| Latanoprost | 1,272 | $17,562 |
| Brimonidine Tartrate | 518 | $16,607 |
| Travoprost | 94 | $16,389 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 864 | $16,044 |
| Cyclosporine | 16 | $13,748 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 50 | $13,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $3,112 | $376,965650 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $302 | $121,234159 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $104 | $18,61539 claims |
| AlconSimbrinza | $969 | $13,65750 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $23 | $2,87215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.